Lung Cancer
NXP900-103: A Phase 1b Clinical Study of NXP900 in Combination with Osimertinib in Subjects with Advanced, EGFR Mut+ Non-Small Cell Lung Cancer
- Details
ClinicalTrials.gov ID:
NCT07315113
Diagnosis Type:
NA
USOR Number:
- Address
,
P: